# US 2022/0031609 A1 · Organic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031609 A1
- Document ID: US20220031609A1
- Status: Published application
- Kind: A1
- Application number: 17/501,173
- Filed: 2021-10-14
- Published: 2022-02-03
- Earliest claimed: 2003-04-08
- Assignees: Novartis AG; Mitsubishi Tanabe Pharma Corporation
- Applicants: Novartis AG; Mitsubishi Tanabe Pharma Corporation
- Inventors: Tomoyuki OOMURA; Madhusudhan PUDIPEDDI; Colleen RUEGGER; Alan Edward ROYCE; Masaki SASAKI; Tokuhiro TAMURA
- Web page: https://patentgrep.com/patent/US20220031609A1

## CPC

- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.

## Claims

### Claim 1

A solid pharmaceutical composition suitable for oral administration, comprising:
(a) a therapeutically effective amount of a S1P receptor agonist, which is 2-amino-2-{2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl}-1,3-propanediol or a pharmaceutically acceptable salt thereof, and
(b) a sugar alcohol.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein the sugar alcohol comprises mannitol.

### Claim 3 (depends on 1)

A composition according to claim 1, further comprising a lubricant.

### Claim 4 (depends on 3)

A composition according to claim 3, wherein the lubricant comprises magnesium stearate.

### Claim 5 (depends on 1)

A composition according to claim 1, comprising 0.5 to 5% by weight of the S1P receptor agonist.

### Claim 6 (depends on 1)

A composition according to claim 1, comprising 90 to 99.5% by weight of the sugar alcohol.

### Claim 7 (depends on 3)

A composition according to claim 3, comprising 1.5 to 2.5% by weight of the lubricant.

### Claim 8 (depends on 1)

A composition according to claim 1, in the form of a tablet.

### Claim 9 (depends on 1)

A composition according to claim 1, in the form of a capsule.

### Claim 10 (depends on 3)

A composition according to claim 3, comprising 0.01 to 5% by weight of the lubricant.

### Claim 11 (depends on 2)

A composition according to claim 2, wherein the S1P receptor agonist is micronized.

### Claim 12 (depends on 2)

A composition according to claim 2, wherein the S1P receptor agonist is pre-screened with a 400 to 500 μm mesh screen.

### Claim 13 (depends on 2)

A method of treating multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to claim 2.

### Claim 14 (depends on 1)

A method of treating multiple sclerosis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to claim 1.

### Claim 15 (depends on 2)

A composition according to claim 2, wherein the mannitol has a mean particle size of 100 to 300 μm.

### Claim 16 (depends on 2)

A composition according to claim 2, wherein the mannitol has a mean particle size of 150 to 250 μm.

### Claim 17 (depends on 2)

A composition according to claim 2, wherein the mannitol has a bulk density of 0.4 to 0.6 g/mL.

### Claim 18 (depends on 2)

A composition according to claim 2, wherein the mannitol has a bulk density of 0.45 to 0.55 g/mL.

### Claim 19 (depends on 2)

A composition according to claim 2, wherein the mannitol has a single point surface area of 1 m2/g to 7 m2/g.

### Claim 20 (depends on 2)

A composition according to claim 2, wherein the S1P receptor agonist is 2-amino-2-{2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl}-1,3-propanediol hydrochloride.
